Clinical trial of DZ13 DNAzyme targeting c-Jun in subjects with Basal Cell Carcinoma - DISCovery (Oligonucleotide Inhibition of Skin Cancer) study

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1017707

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Basal cell carcinoma (BCC) is the commonest skin cancer in Australia that is highly invasive. Surgical removal is its main treatment option but causes scarring and is impractical when there are multiple cancers. C-Jun, a molecule promoting cell growth is present in abnormally large amount in BCC compared to normal cells. Dz13 targets and destroys these molecules, killing cancer cells when injected into the tumour. Dz13 may hence become a more effective and aesthetic alternative of treating BCC.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2012

Funding Scheme: NHMRC Postgraduate Scholarships

Funding Amount: $74,365.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Dermatology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

basal cell carcinoma | cancer research | cancer treatment | clinical patient management | molecular oncology | skin cancer

Related Links